ArticleThe pharmacogenomics journal2005
Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3).
Article in The pharmacogenomics journal, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00187668 (Study Of PHarmacogenetics in Ethnically Diverse Populations), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study Of PHarmacogenetics in Ethnically Diverse Populations (SOPHIE Study)
Who cites it
19 citing papers in PubMed, 55 citations in OpenAlex.
- Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017Trial
- Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders.BMC neurology · 2017Trial
- Cardioprotective SNPs in SLC28A3 and lncRNA SLC28A3-AS1 result in transcriptional changes and alternative splicing to reduce doxorubicin cytotoxicity.Human molecular genetics · 2026Article
- Cladribine as a Potential Object of Nucleoside Transporter-Based Drug Interactions.Clinical pharmacokinetics · 2022Review
- Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine.Clinical pharmacokinetics · 2021Review
- Cell-surface SLC nucleoside transporters and purine levels modulate BRD4-dependent chromatin states.Nature metabolism · 2021Article
- Concentrative Nucleoside Transporter 3 Is Located on Microvilli of Vaginal Epithelial Cells.ACS omega · 2020Article
- Article
- Rosetta Broker for membrane protein structure prediction: concentrative nucleoside transporter 3 and corticotropin-releasing factor receptor 1 test cases.BMC structural biology · 2017Article
- Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.Frontiers in pharmacology · 2015Review
- Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia.Journal of human genetics · 2013Article
- Pharmacogenetics and pharmacoepigenetics of gemcitabine.Medical oncology (Northwood, London, England) · 2010Review
- The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology.Clinical pharmacology and therapeutics · 2010Review
- Pharmacogenomic discovery using cell-based models.Pharmacological reviews · 2009Review
- Ocular toxicity of fludarabine: a purine analog.Expert review of ophthalmology · 2008Article
- Sequence variation and linkage disequilibrium in the GABA transporter-1 gene (SLC6A1) in five populations: implications for pharmacogenetic research.BMC genetics · 2007Article
- Concentrative nucleoside transporters (CNTs) in epithelia: from absorption to cell signaling.Journal of physiology and biochemistry · 2007Review
- Functional genomics of membrane transporters in human populations.Genome research · 2006Article
- Contribution of tumoral and host solute carriers to clinical drug response.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
The human concentrative nucleoside transporter, CNT3 (SLC28A3), plays an important role in mediating the cellular entry of a broad array of physiological nucleosides and synthetic anticancer nucleoside analog drugs. As a first step toward understanding the genetic basis for interindividual differences in the disposition and response to antileukemic nucleoside analogs, we examined the genetic and functional diversity of CNT3. In all, 56 variable sites in the exons and flanking intronic region of SLC28A3 were identified in a collection of 270 DNA samples from US populations (80 African-Americans, 80 European-Americans, 60 Asian-Americans, and 50 Mexican-Americans). Of the 16 coding region variants, 12 had not been previously reported. Also, 10 resulted in amino-acid changes and three of these had total allele frequencies of >/=1%. Nucleotide diversity (pi) at nonsynonymous and synonymous sites was estimated to be 1.81 x 10(4) and 18.13 x 10(4), respectively, suggesting that SLC28A3 is under negative selection. All nonsynonymous variants, constructed by site-directed mutagenesis and expressed in Xenopus laevis oocytes, transported purine and pyrimidine model substrates, except for c. 1099G>A (p. Gly367Arg). This rare variant alters an evolutionarily conserved site in the putative substrate recognition domain of CNT3. The presence of three additional evolutionarily conserved glycine residues in the vicinity of p. Gly367Arg that are also conserved in human paralogs suggest that these glycine residues are critical in the function of the concentrative nucleoside transporter family. The genetic analysis and functional characterization of CNT3 variants suggest that this transporter does not tolerate nonsynonymous changes and is important for human fitness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.